'The majority of transmission will be via people who are within two metres of one another.' 'The closer you are, the more likely that you'll be infected.'
Low growth visibility and trouble with regulators have resulted in lack of interest from investors
Even as the Supreme Court had recently dismissed the industry's plea against prices fixed by the regulator and its timely implementation, the National Pharmaceutical Pricing Authority has asked companies to pay the overcharged dues with 15 per cent interest.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries:
FMCG, durables, pharma firms say they remain unclear about transition gains and losses
Total exit value breached the $10 billion mark for the first time to touch $10.3 billion this calendar, from $9.4 billion in 2015
.jpg)
The move is expected to delay the introduction of low-priced medicines in the market.
The sentiment-driven rally also got support from stock specific earning results and Finance Minister Arun Jaitley's statement that the Centre will step up reforms to attract more investment and fill up infrastructure deficit.
Dilip Shanghvi has never tried to be everything to everybody.
Hero MotoCorp's promoter Pawan Munjal emerged as the highest paid director.
Of the 30-share Sensex, 13 ended higher, while 17 led by Power Grid, Tata Steel, Bajaj Auto, Hero MotoCorp, NTPC, Tata Motors, Dr Reddy's, M&M, GAIL, Infosys and L&T finished lower, fell by up to 2.40 per cent
An innovator creates intellectual property for a need no one knows exists, says Chandru Chawla.
Benchmark indices plunge 4.7% in the first full week of 2016.
Analysts say those taking exposure through stocks could look at firms focused on domestic business
The 50-share NSE Nifty was trading lower by 24 points.
Ajit Mishra, Vice President, Research, Religare Broking, answers readers' queries on stocks they own or want to buy.
'Pay-for-delay' settlements between drug patent-holders and generics manufacturers to delay the launch of cheaper generic medicine are increasingly being scrutinised by antitrust regulators
The BSE Midcap and Smallcap indices underperformed the largecaps and ended over 1% lower.
.jpg)
The debt-equity ratio was as high as 1.4 times the net worth as certificates of deposit and inter-corporate deposits gained popularity.
While the government's demonetisation move is aimed at curbing under-invoicing, the worry was that retailers would de-stock in the short term, impacting sales.
Earning woes drag markets lower; TCS, HUL lead fall.
Dilip Shanghvi founded Sun Pharma in 1983.
The Delhi High Court on Friday stayed the ban on some fixed dose combination (FDC) drugs of Glaxo SmithKline, Wockhardt and Laboratories Griffon but said action against their sale could be taken in the absence of valid sale and marketing licence.
Better-than-expected financial results in Q3 due to higher revenue growth and margins in key markets fuel the rally
Asian markets were trading mixed with the Nikkei gaining after the US dollar strengthened against the yen.
The BSE benchmark index is yet to give any indication on the monthly Fibonacci charts.
The recovery was led by pharma majors led by Dr Reddy's Labs.
Indian loses chance to be research hub as domestic drug companies move R&D overseas.
The former McKinsey India head is presently on board of many big Indian conglomerates.
Geopolitical concerns, earnings sees investors rush to safe haven plays post the Union Budget presentation in July.
Expectations of strong results, consistent performance and investors preference for stocks in the defensive space help the sector outshine broader markets.
Instead of being carried away by Friday's historic election verdict, savvy investors were seen taking money off the table, after the benchmark Sensex rallied about 1,500 points in intra-day trade.
The local markets are expected to react to global triggers until the government announces the Union Budget.
Of these, three stocks belong to the automobile pack and two are from the pharma.
Infosys, TCS, ICICI Bank and Sun Pharma among the top losers of the hour.
In peace and at war, firms remain tethered to promoter families in a uniquely Indian way.
India had been engaged in a contentious battle with the US over the issue, especially in the pharmaceutical sector.
Index heavyweight RIL surged 3% to end above Rs 1,000 mark while IT majors were also the top gainers.
Ajit Mishra, Vice President, Research, Religare Broking, answers readers's queries on stocks they own or want to buy.
The latest price revision includes mostly cardiovascular drugs, anti-bacterials, anti-herpes, contraceptives and gastrointestinal medicines
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances